| 15.48 0.01 (0.06%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.34  |
1-year : | 20.65 |
| Resists | First : | 16.56 |
Second : | 17.68 |
| Pivot price | 15.64 |
|||
| Supports | First : | 14.75 | Second : | 12.27 |
| MAs | MA(5) : | 15.45  |
MA(20) : | 15.94 |
| MA(100) : | 17.21 |
MA(250) : | 16.69 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 37.3 |
D(3) : | 32.5 |
| RSI | RSI(14): 35.6 |
|||
| 52-week | High : | 21.88 | Low : | 12.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SIBN ] has closed above bottom band by 40.7%. Bollinger Bands are 38.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.76 - 15.84 | 15.84 - 15.91 |
| Low: | 15.24 - 15.33 | 15.33 - 15.4 |
| Close: | 15.35 - 15.48 | 15.48 - 15.6 |
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Fri, 20 Feb 2026
A Look Ahead: SI-BONE's Earnings Forecast - Benzinga
Tue, 17 Feb 2026
SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026 - Bitget
Mon, 16 Feb 2026
Earnings Preview: Si-Bone (SIBN) Q4 Earnings Expected to Decline - Finviz
Fri, 13 Feb 2026
SI-BONE, Inc. (SIBN) Stock Analysis: A 69.56% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Sat, 07 Feb 2026
More Unpleasant Surprises Could Be In Store For SI-BONE, Inc.'s (NASDAQ:SIBN) Shares After Tumbling 27% - 富途牛牛
Mon, 02 Feb 2026
SI-BONE, Inc. to Announce Q4 and Full Year 2025 Financial Results on February 23, 2026 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 43 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 106.5 (%) |
| Shares Short | 2,590 (K) |
| Shares Short P.Month | 2,430 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.98 |
| Profit Margin | -11.3 % |
| Operating Margin | -11.1 % |
| Return on Assets (ttm) | -6.9 % |
| Return on Equity (ttm) | -13 % |
| Qtrly Rev. Growth | 20.6 % |
| Gross Profit (p.s.) | 3.55 |
| Sales Per Share | 4.46 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -30.36 |
| PEG Ratio | 0 |
| Price to Book value | 3.88 |
| Price to Sales | 3.46 |
| Price to Cash Flow | -546.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|